Louisiana Sheriffs’ Pension & Relief Fund v. Cardinal Health, Inc.
|Court:||United States District Court of the Southern District of Ohio|
|Class Period:||03/02/2015 - 05/02/2018|
|Case Contacts:||Avi Josefson, Michael D. Blatchley, Scott R. Foglietta|
Securities class action lawsuit on behalf of its client Louisiana Sheriffs’ Pension & Relief Fund (“Louisiana Sheriffs”) against Cardinal Health, Inc. (“Cardinal” or the “Company”) (NYSE: CAH), and certain of the Company’s senior executives (collectively, “Defendants”). The action, which is captioned Louisiana Sheriffs’ Pension & Relief Fund v. Cardinal Health, Inc., No. 2:19-cv-03347-EAS-EPD (S.D. Ohio), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of all purchasers of Cardinal common stock between March 2, 2015 and May 2, 2018, inclusive (the “Class Period”).
Cardinal is a global, integrated healthcare services and products company. This action arises from Defendants’ misrepresentations and omissions relating to Cardinal’s integration of Cordis Corp. (“Cordis”), a medical device manufacturer Cardinal purchased from Johnson & Johnson in March 2015, and the inventory and supply chain problems at Cordis.
The Complaint alleges that, throughout the Class Period, Defendants misled investors by stating that Cordis would benefit from Cardinal’s advanced inventory management and supply chain information technology solutions. Defendants also falsely represented that the Company properly “reserve[d] for inventory obsolescence” and that “[i]nventories presented in the consolidated balance sheets [were] net of reserves for excess and obsolete inventory.” As a result of these misrepresentations, Cardinal shares traded at artificially inflated prices throughout the Class Period.
The truth began to emerge on August 2, 2017, when Cardinal reported weak earnings for its fourth quarter and fiscal year 2017 and lowered its earnings guidance for fiscal year 2018 due in part to “higher-than-planned write-offs for excess inventory” at Cordis. Defendants, however, falsely assured Cardinal’s investors that Cordis’s operational deficiencies had been addressed, that the Company had built the necessary infrastructure and IT systems for Cordis such that it now had “visibility” of Cordis’s inventory, and that the Cordis business was “going into a phase of a lot more stability.” Despite Defendants’ attempt to soften Cordis’s poor performance, the price of Cardinal stock declined from a closing price of $77.33 per share on August 1, 2017, to a closing price of $70.99 per share on August 2, 2017.
Then, on May 3, 2018, Cardinal announced disappointing results for its third quarter fiscal year 2018 and cut its fiscal year 2018 earnings guidance. The Company explained that the “biggest variable driving these results” was the “disappointing performance” of the Cordis business. Contrary to the Company’s prior statements that it had visibility into Cordis’s inventory and that the Company properly reserved for obsolete inventory, the Company revealed that after launching a new global supply chain IT platform over the last quarter at Cordis, it discovered millions of dollars of unsellable and expired heart stents and catheters stationed overseas that had to be written off. As a result of these disclosures, the price of Cardinal’s stock declined from a closing price of $64.65 per share on May 2, 2018, to a closing price of $50.80 per share on May 3, 3018.
If you wish to serve as Lead Plaintiff for the Class, you must file a motion with the Court no later than September 30, 2019, which is the first business day on which the U.S. District Court for the Southern District of Ohio is open that is 60 days after the publication date of August 1, 2019. Any member of the proposed Class may move the Court to serve as Lead Plaintiff through counsel of their choice. Members may also choose to do nothing and remain part of the proposed Class.
Louisiana Sheriffs is represented by BLB&G. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Avi Josefson of BLB&G at 212-554-1493, or via e-mail at email@example.com.
Other Cases of Interest
- Chemours Company
District of Delaware Hannah Ross, Avi Josefson, Michael D. Blatchley, Gregory V. Varallo
- Impinj, Inc.
Western District of Washington Jonathan D. Uslaner, Michael D. Blatchley, Lauren M. Cruz
- Cardinal Health, Inc.
Southern District of Ohio Avi Josefson, Michael D. Blatchley, Scott R. Foglietta
- EQT Corporation
Western District of Pennsylvania Avi Josefson
- Spectrum Brands Holdings, Inc.
Western District of Wisconsin Avi Josefson, Katherine M. Sinderson, Jai K. Chandrasekhar, Matthew Traylor
District of Minnesota Michael D. Blatchley, Michael Mathai
- Venator Materials PLC
Southern District of New York Avi Josefson, Michael D. Blatchley, Scott R. Foglietta
- Karyopharm Therapeutics Inc.
District of Massachusetts Avi Josefson, Hannah Ross, Michael D. Blatchley, Scott R. Foglietta
- Quality Systems, Inc.
Central District of California Gerald H. Silk, Avi Josefson